Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia.

Brain : a journal of neurology·2006
Same author

Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease.

Neuropathology and applied neurobiology·2006
Same author

Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.

Journal of neurology, neurosurgery, and psychiatry·2006
Same author

The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males.

Journal of neurology, neurosurgery, and psychiatry·2006
Same author

A polymorphic variation in the interleukin 1A gene increases brain microglial cell activity in Alzheimer's disease.

Journal of neurology, neurosurgery, and psychiatry·2004
Same author

Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease.

Journal of neurology, neurosurgery, and psychiatry·2004
Same journal

Diagnostic Alteration Is Not Therapeutic Dependency: Lessons From Failed RET Inhibition in a PLAG-Altered CNS Embryonal Tumour.

Neuropathology and applied neurobiology·2026
Same journal

Respone to Škudar.

Neuropathology and applied neurobiology·2026
Same journal

Unravelling the Significance of Cystatin C and Bunina Bodies in Amyotrophic Lateral Sclerosis Pathogenesis.

Neuropathology and applied neurobiology·2026
Same journal

Neuropathological and Molecular Features Associated With a Heterozygous DNAJC7 Mutation in Amyotrophic Lateral Sclerosis.

Neuropathology and applied neurobiology·2026
Same journal

Central Nervous System Embryonal Tumour With PLAGL Amplification Lacking Typical Embryonal Morphology: Diagnostic Pitfall in a Paediatric Case.

Neuropathology and applied neurobiology·2026
Same journal

Lewy Bodies Are Not Associated With Neuronal or Synaptic Loss in Dementia With Lewy Bodies.

Neuropathology and applied neurobiology·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Review: Recent progress in frontotemporal lobar degeneration.

S M Pickering-Brown1

  • 1Clinical Neurosciences Research Group, Faculty of Human and Medical Sciences, University of Manchester, Manchester, UK. spb@manchester.ac.uk

Neuropathology and Applied Neurobiology
|October 14, 2009
PubMed
Summary
This summary is machine-generated.

Frontotemporal lobar degeneration (FTLD) is a familial dementia. Recent advances in understanding FTLD pathophysiology include identifying progranulin and TDP-43 proteins, with TDP-43 showing biomarker potential.

More Related Videos

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

Related Experiment Videos

Last Updated: Jun 19, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

Area of Science:

  • Neurology
  • Genetics
  • Pathology

Background:

  • Frontotemporal lobar degeneration (FTLD) is a significant and increasingly recognized form of dementia.
  • The condition is characterized by a high degree of familial inheritance.
  • Challenges in research include inconsistent nomenclature, which consensus recommendations aim to resolve.

Purpose of the Study:

  • To review current concepts and recent advancements in the understanding of Frontotemporal lobar degeneration (FTLD).
  • To highlight progress in the clinical, pathological, and genetic aspects of FTLD.
  • To discuss newly identified proteins involved in FTLD pathophysiology.

Main Methods:

  • Literature review of recent advances in FTLD research.
  • Synthesis of current knowledge on clinical, pathological, and genetic findings.
  • Focus on newly identified proteins and potential biomarkers.

Main Results:

  • Significant progress has been made in understanding FTLD's clinical, pathological, and genetic landscape.
  • Progranulin and TDP-43 have been identified as key proteins in FTLD pathophysiology.
  • TDP-43 shows potential as a biomarker for FTLD.

Conclusions:

  • Recent discoveries have advanced the understanding of FTLD.
  • Further research is needed to fully elucidate the genetic causes and biological pathways of FTLD.
  • Standardized nomenclature and continued research are crucial for FTLD.